tiprankstipranks
MDB Capital Holdings, LLC Class A (MDBH)
NASDAQ:MDBH
US Market
Want to see MDBH full AI Analyst Report?

MDB Capital Holdings, LLC Class A (MDBH) Earnings Dates, Call Summary & Reports

14 Followers

Earnings Data

Report Date
May 27, 2026
After Close (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
Last Year’s EPS
-0.66
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Mar 31, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call emphasized significant operational progress and strategic positioning (notably rapid AI-driven diligence improvements, building two discrete monetizable assets in MDB Direct and PatentVest, a clearer path to lower run-rate OpEx, and a sizable pipeline with several assets that management believes have $1B potential). However, the company faces material near-term challenges: a prolonged public stock decline, difficult microcap market conditions, a critical distribution gap needed to scale launches, execution issues at some portfolio companies, and ongoing financing/valuation uncertainty for spinouts. The tone is optimistic about future scalability but pragmatic about the risks and uncertainty in execution and market reception.
Company Guidance
MDB said it plans to scale from its historic cadence of one launch every 18 months to 3–5 launches per year, driven by AI gains over the past 90–120 days that it says can compress diligence by ~2/3 (example: patentability reviews from ~45 hours to ~1.5 hours) and cut IPO prep from 6–18 months to weeks. Financially, management reported ~ $10M in fixed OpEx, $5.7M cash burn for the year (including ~ $4M invested annually since the IPO in MDB Direct and PatentVest), which implies a pro‑forma burn of ~ $1.7M after excluding those investments and a projected post‑spinout OpEx of ~ $6M/year; cash and marketable securities less current liabilities totaled ~ $22.3M at year‑end. Portfolio metrics cited: eXoZymes ~ $45M year‑end market value (current stake ≈ $30M), 7.1M Paulex shares (IPO and planned clinical trial this year), a U.S. patent‑prosecution TAM of $10–15B, 18 historical IPOs over 29 years, ~675 active accounts out of a few thousand shareholders, and management’s view that each principal asset has potential to reach a $1B valuation.
AI-Driven Diligence Acceleration
Management reports AI reduced diligence inertia dramatically: they estimate compressing time-to-answer by ~2/3 (≈66.7%). Patentability analyses that previously took ~45 hours are now done in ~1.5 hours (≈96.7% faster). S-1 preparation that historically took 6–18 months is expected to be achievable in weeks, enabling far faster company launches.
Strategic Asset Build: MDB Direct (clearing) and PatentVest
Company invested roughly $4.0M annually (since the IPO) into MDB Direct and PatentVest to build them as discrete assets. MDB Direct (self-clearing capability) is operational and management is in active strategic-partner discussions; comparable clearing firms have sold for 'tens of millions.' PatentVest is operating as an ABS IP law firm, with the U.S. patent prosecution market sized at an estimated $10–15B opportunity. Both assets are planned to be financed as independent entities and pursued for monetization/spinout.
Improved Financial Leverage and Lower Run-Rate Post-Spinouts
Reported year-end net cash/current assets (cash + marketable securities less current liabilities) of approximately $22.3M. Annual fixed operating expenses are about $10M; reported cash burn for the year was $5.7M. Management states the $4M invested in clearing/PatentVest is part of that OpEx — excluding that would imply a $1.7M net burn. After spinning out the clearing platform and PatentVest, OpEx is expected to fall to about $6M annually, improving leverage as the firm scales launches.
Pipeline Scalability and Portfolio Upside
Management reiterates the target to scale to 3–5 company launches per year. Principal portfolio assets highlighted with large upside: eXoZymes (year-end market value ~ $45M; current holding ~ $30M), Paulex (7.1M shares owned; IPO planned later this year and clinical trial initiation targeted for September), and other co-founded assets with perceived $1B upside potential. Management emphasizes capital efficiency for certain portfolio companies, notably eXoZymes, which they expect will require relatively modest dilution due to grant funding and outsourced manufacturing.
Operational and Clinical Progress Across Portfolio
Notable operational milestones: HeartBeam received FDA clearance for its ambulatory 12-lead ECG device (positioned as highly sensitive and partnership-worthy); Cue Biopharma has partnerships (Boehringer Ingelheim, ImmunoScape) and is preparing a 401 study; eXoZymes has progressed technologies to contract manufacturers demonstrating scalable biomanufacturing; Buda (fresh-juice chain) is profitable and positioned for retail expansion.

MDB Capital Holdings, LLC Class A (MDBH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

MDBH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 27, 2026
2026 (Q1)
- / -
-0.662
Mar 31, 2026
2025 (Q4)
- / -0.17
-0.66273.87% (+0.49)
Nov 20, 2025
2025 (Q3)
- / -0.46
-0.948.56% (+0.44)
Aug 27, 2025
2025 (Q2)
- / -0.83
-0.46-80.22% (-0.37)
May 21, 2025
2025 (Q1)
- / -
-0.776
Mar 31, 2025
2024 (Q4)
- / -0.66
-0.77614.69% (+0.11)
Nov 21, 2024
2024 (Q3)
- / -0.90
-0.324-177.78% (-0.58)
Apr 17, 2024
2023 (Q4)
- / -0.78
-0.202-284.16% (-0.57)
Nov 15, 2023
2023 (Q3)
- / -0.32
-0.224-44.64% (-0.10)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

MDBH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 31, 2026
$2.98$3.19+7.05%
Nov 20, 2025
$3.38$3.26-3.55%
Aug 27, 2025
$3.45$3.50+1.45%
May 21, 2025
$4.76$4.70-1.26%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MDB Capital Holdings, LLC Class A (MDBH) report earnings?
MDB Capital Holdings, LLC Class A (MDBH) is schdueled to report earning on May 27, 2026, After Close (Confirmed).
    What is MDB Capital Holdings, LLC Class A (MDBH) earnings time?
    MDB Capital Holdings, LLC Class A (MDBH) earnings time is at May 27, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is MDBH EPS forecast?
          Currently, no data Available